Clinical Trial Search

Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042

Primary: Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life…

Primary: Related Adverse Events — 1; 1 number of participants

Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years

Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633

Primary: Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL) — 19 participants w histological clearance

Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants

Primary: Pathological Response — 20; 24 participants

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants

Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877

Primary: Overall Response Rate at 48 Weeks — 10 Participants

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants

Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…

Primary: Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment. — 95; 69; 63; 57 percentage of patients

Primary: Objective Response Rate (ORR) — 13.8 percentage of participants

Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350

Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants

Primary: Complete Response Through 1 Year — 38; 16 participants

Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…

Primary: Performance Characteristics: Sensitivity (SN), Specificity (SP), Positive Predictive Value (PPV) and Negative Predictive Values (NPV) — 90.0; 76.9; 100.0; 65.6…

Primary: Compliance With Annual Anal HPV DNA Screening — 107; 89; 13; 31 Participants

Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants

Primary: Percentage of Participants With a Diagnosis of ≥ CIN2 — 14.0; 0.8 Percentage of participants

Primary: Difference in Adenomas Per Colonoscopy (APC) — 0.60; 0.74 Resected adenomas — p=0.0002

Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants

Primary: Diagnostic Accuracy of In-vivo Polyp Assessment — 93.3; 94.7 % diagnostic accuracy

Primary: Presence of Squamocolumnar Cells — 11; 8; 12; 19 Participants